Đánh giá đáp ứng của phác đồ TCF điều trị ung thư biểu mô vẩy vùng họng - miệng giai đoạn III-IV (MO)

Purpose: To evaluate the effect of neoadjuvante chemotherapy TCF x 3 cycles for 43 pts locally advanced head and neck cancer stage III-IV (MO). Results: OS 79.1 percent, CR 30.2 percent, PR 48.9 percent. Neutropenia 22.5 percent. Neutropenia grade 3.4 in CR groupe is 3 times higher in comparing with others, p0.05. Conclusion: neoadjuvante chemotherapy TCF is effective, side-effect is hematology toxicity.